IN THE NEWS
Innogenetics Concludes Settlement and Licensing Agreement in the Field of Hepatitis C Diagnostics
Westbrook Warm to Needle Exchange: A program based in Portland [Maine] wants to expand to Westbrook, where many of its clients live. “Needle exchanges have been criticized by people who believe such programs condone and even increase drug use. Operators of a needle-exchange program in Portland are looking to open a satellite operation in Westbrook. While the program for injection drug users is operated by Portland's Public Health Division, it is a regional resource funded by state money and foundation grants. A survey of clients revealed that many live in Westbrook, though the exact number was not available on Tuesday.”
Scientists Discover Better Treatment for Hepatitis C
ACG: Gene Expression Predicts Sustained Response in Chronic Hepatitis C
Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
Discovery of New Antiviral Mechanism in Mammals May Improve Treatment of Hepatitis C Infections
[United Kingdom] ACTION is Being Taken to Combat the Rising Number of Hepatitis C Infections in Herefordshire
Cubist Gets Option to Acquire Illumigen
Hepatitis C: A Challenge to Physicians
The disease is often asymptomatic, there's no vaccine and it kills 8,000 to 10,000 people a year
Japan Probes Failure to Notify Patients at Risk of Hepatitis C from Tainted Blood
Hepatitis C Testing Recommended For Anyone With A Tattoo
[Australia] Hep C Infection After Test Missed
The Basics: The Asterisk on Cancer Deaths
Watchdog Blood Database Set Up
[EU] Experts Caution Against Hidden Hepatitis C Spread
[Tasmania] Tassie Turns Blind Eye to Hep C
Vertex Hep C Drug Shows Real Promise, Limitations
New Therapeutic Vaccine May Offer Hope for Chronic Hepatitis C Patients
Hepatitis C Testing in Nottingham Marks World Hepatitis Awareness Day
Safe Syringes Could Avert 1.3 million Deaths a Year: WHO
CLINICAL TRIALS, COHORT STUDIES, AND PILOT STUDIES
Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. Arase Y, et al. J Med Virol. 2007 Oct;79(10):1485-90.
Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C. Kowala-Piaskowska A, et al. Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1095-103.
Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C. Carr C, et al. Liver Int. 2007 Oct;27(8):1111-8.
Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease. Masarone M, et al. J Viral Hepat. 2007 Oct;14(10):714-20.
Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. Di Bisceglie AM, et al. J Viral Hepat. 2007 Oct;14(10):721-9.
Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. Tanaka A, et al. World J Gastroenterol. 2007 Oct 21;13(39):5180-7.
Clinical trial: comparison of weekly once versus twice half-dose weekly administration of pegylated interferon alpha 2b in combination with ribavirin for the treatment of HCV-1 positive patients with chronic hepatitis C. Sebastiani G, et al. Aliment Pharmacol Ther. 2007 Oct 1;26(7):1077-82.
Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. Ko C, Siddaiah N, et al. Liver Int. 2007 Oct 10; [Epub ahead of print]
Response of combination therapy on viral load and disease severity in chronic hepatitis C. Kumar D, et al. Dig Dis Sci. 2007 Oct 13; [Epub ahead of print]
Hepatitis C virus and risk of non-Hodgkin lymphoma in British Columbia, Canada. Spinelli JJ, et al. Int J Cancer. 2007 Oct 12; [Epub ahead of print]
Hepatitis C virus infection in Italian patients with fibromyalgia. Palazzi C, et al. Clin Rheumatol. 2007 Oct 18; [Epub ahead of print]
31P MR spectroscopy in assessment of response to antiviral therapy for hepatitis C virus-related liver disease. Lim AK, et al. AJR Am J Roentgenol. 2007 Oct;189(4):819-23.
Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alpha-2a (40KD) plus ribavirin. Snoeck E, et al. Liver Int. 2007 Oct 26; [Epub ahead of print]
Detection of HCV by PCR in serum and PBMC of patients with hepatitis C after treatment. Cavalheiro Nde P, Filgueiras et al. Braz J Infect Dis. 2007 Oct;11(5):471-4
UK prospective study of change in visual function in patients treated with Peginterferon alpha for hepatitis C. Malik NN, et al. Br J Ophthalmol. 2007 Oct 25; [Epub ahead of print]
Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy. Carta MG, et al. Clin Pract Epidemol Ment Health. 2007 Oct 23;3(1):22 [Epub ahead of print]
Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Kamal SM, et al. Hepatology. 2007 Oct 17; [Epub ahead of print]
Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. Kato J, et al. J Gastroenterol. 2007 Oct;42(10):830-6. Epub 2007 Oct 15.
Liver cancer and hepatitis B and C in New South Wales, 1990-2002: a linkage study. Amin J, et al. Aust N Z J Public Health. 2007 Oct;31(5):475-82.
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. McHutchison JG, et al. Hepatology. 2007 Oct 10;46(5):1341-1349 [Epub ahead of print]
Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. Diago M, et al. Aliment Pharmacol Ther. 2007 Oct 15;26(8):1131-8.
Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. Jeong SC, et al. World J Gastroenterol. 2007 Oct 28;13(40):5343-50.
Accordion Index: A new tool for the prediction of the efficacy of peg-interferon-alpha-2b and ribavirin combination therapy for chronic hepatitis C. Satoh T, Masumoto A. Hepatol Res. 2007 Oct 10; [Epub ahead of print]
The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. Fabrizi F, et al. J Viral Hepat. 2007 Oct;14(10):697-703.
BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES
Relationship of peripheral blood CD4-positive T cells to carcinogenesis in patients with HCV-related chronic hepatitis and liver cirrhosis. Matsui T, et al. Cancer Chemother Pharmacol. 2007 Oct 12; [Epub ahead of print]
Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon. Ikeda M, Kato N. J Pharmacol Sci. 2007 Oct;105(2):145-50. Epub 2007 Oct 6.
HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Pilli M, et al. Gastroenterology. 2007 Oct;133(4):1132-43. Epub 2007 Jul 3.
Vaccination Against Hepatitis C Virus With Dendritic Cells Transduced With an Adenovirus Encoding NS3 Protein. Zabaleta A, et al. Mol Ther. 2007 Oct 9; [Epub ahead of print]
Interactive effects of immunoglobulin gamma and human leucocyte antigen genotypes on clearance and persistence of infection with hepatitis C virus. Pandey JP, et al. Clin Exp Immunol. 2007 Oct 9; [Epub ahead of print]
Innate immunity in hepatitis C virus infection: Interplay among dendritic cells, natural killer cells and natural killer T cells. Kanto T, Hayashi N. Hepatol Res. 2007 Oct;37 Suppl 3:S319-26.
Hepatitis C virus NS3/4A protein interacts with ATM, impairs DNA repair and enhances sensitivity to ionizing radiation. Lai CK, Virology. 2007 Oct 9; [Epub ahead of print]
Comparative Studies on Expression of alpha-Smooth Muscle Actin in Hepatic Stellate Cells in Chronic Hepatitis B and C. Chu CM, et al. Dig Dis Sci. 2007 Oct 13; [Epub ahead of print]
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Timpe JM, et al. Hepatology. 2007 Oct 16; [Epub ahead of print]
Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance. Itou M, et al. J Gastroenterol Hepatol. 2007 Oct 17; [Epub ahead of print]
Effects on protease inhibition by modifying of helicase residues in hepatitis C virus nonstructural protein 3. Dahl G, et al. FEBS J. 2007 Oct 19; [Epub ahead of print]
Increased T-Cell Sinusoidal Lymphocytosis in Liver Biopsies in Patients With Chronic Hepatitis C and Mixed Cryoglobulinemia. Carmack S, et al. Am J Gastroenterol. 2007 Oct 26; [Epub ahead of print]
Clonal expansion of IgM+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Charles ED, et al. Blood. 2007 Oct 17; [Epub ahead of print]
Mutations in the interferon sensitivity determining region (NS5A aa 2209-2248) in patients with hepatitis C 1b infection and correlating response to combined therapy of pegylated interferon and ribavirin.Yen YH, et al. Aliment Pharmacol Ther. 2007 Oct 26; [Epub ahead of print]
Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study. Tural C, et al. J Viral Hepat. 2007 Oct;14(10):704-13.
Characteristics and survival of HIV-infected patients not screened for hepatitis C virus infection in a hospital-based cohort. Bénet T, et al. J Viral Hepat. 2007 Oct;14(10):730-5.
Cryoglobulinaemia associated with hepatitis C virus: influence of HCV genotypes, HCV-RNA viraemia and HIV coinfection. Ramos-Casals M, et al. J Viral Hepat. 2007 Oct;14(10):736-42.
Awareness of Hepatitis C Infection Among Women With and At Risk for HIV. Cohen MH, et al. J Gen Intern Med. 2007 Oct 9; [Epub ahead of print]
Increase in newly acquired hepatitis C in HIV positive men who have sex with men across London and Brighton, 2002-2006. Is this an outbreak? Giraudon I, et al. Sex Transm Infect. 2007 Oct 11; [Epub ahead of print]
Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. Pineda JA, et al. J Antimicrob Chemother. 2007 Oct 14; [Epub ahead of print]
Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": Modifications in two large surveys between 2004 and 2006. Cacoub P, et al. J Hepatol. 2007 Oct 2; [Epub ahead of print]
Managing symptomatic drug-induced liver injury in HIV-hepatitis C virus-coinfected patients: a role for interferon. McGovern BH, et al. Clin Infect Dis. 2007 Nov 15;45(10):1386-92. Epub 2007 Oct 15.
Impact of hepatitis C virus coinfection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 disease. Santin M, et al. Eur J Clin Microbiol Infect Dis. 2007 Oct 16; [Epub ahead of print]
Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring. Slish J, et al. Ther Drug Monit. 2007 Oct;29(5):560-5.
COMPLEMENTARY AND ALTERNATIVE THERAPIES
Plasmatic vitamin C in nontreated hepatitis C patients is negatively associated with aspartate aminotransferase. Souza Dos Santos RM, et al. Liver Int. 2007 Oct 10; [Epub ahead of print]
Inhibition of HCV Replicon Cell Growth by 2-Arylbenzofuran Derivatives Isolated from Mori Cortex Radicis. Lee HY, et al. Planta Med. 2007 Oct 18; [Epub ahead of print]
Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Rambaldi A, et al. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003620.
Bile acids for viral hepatitis. Chen W, et al. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003181.
L: -Carnitine Treatment Reduces Steatosis in Patients with Chronic Hepatitis C Treated with alpha-Interferon and Ribavirin. Romano M, Dig Dis Sci. 2007 Oct 16; [Epub ahead of print]
Antioxidant therapy for chronic hepatitis C after failure of interferon: results of phase II randomized, double-blind placebo controlled clinical trial. Gabbay E, et al. World J Gastroenterol. 2007 Oct 28;13(40):5317-23.
Gauging acceptance of a hepatitis C test by family planning clinic attendees in Glasgow, UK. Sharp L, et al. J Fam Plann Reprod Health Care. 2007 Oct;33(4):263-6.
Assessment of the PHQ-9 as a Screening Tool for Depression in Patients with Chronic Hepatitis C. Dbouk N, et al. Dig Dis Sci. 2007 Oct 13; [Epub ahead of print]
A Cost-Identification Analysis of Screening and Surveillance of Hepatitis C Infection in a Prospective Cohort of Dialysis Patients. Somsouk M, et al. Dig Dis Sci. 2007 Oct 13; [Epub ahead of print]
The Accuracy of Sonography in Predicting Steatosis and Fibrosis in Chronic Hepatitis C. Chen CH, et al. Dig Dis Sci. 2007 Oct 16; [Epub ahead of print]
Bacterial and viral contamination of reusable sharps containers in a community hospital setting. Runner JC. Am J Infect Control. 2007 Oct;35(8):527-30.
Epidemiology of needlesticks and other sharps injuries and injection safety practices in the Dominican Republic. Moro PL, et al. Am J Infect Control. 2007 Oct;35(8):552-9.
Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study. Nguyen OK, et al. Int J Drug Policy. 2007 Oct;18(5):447-51. Epub 2007 Feb 21.
HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Hagan H, et al. Int J Drug Policy. 2007 Oct;18(5):341-51. Epub 2007 May 2.
Evaluation of the available anti-HCV antibody Detection Tests and RT-PCR assay in the Diagnosis of Hepatitis C Virus Infection. Tashkandy MA, et al. Saudi J Kidney Dis Transpl. 2007 Oct-Dec;18(4):523-31.
Meta-analyses of Fibrotest diagnostic value in chronic liver disease. Poynard T, et al. BMC Gastroenterol. 2007 Oct 15;7(1):40 [Epub ahead of print]
Low perceived benefits and self-efficacy are associated with hepatitis C virus (HCV) infection-related risk among injection drug users. Cox J, et al. Soc Sci Med. 2007 Oct 5; [Epub ahead of print]
Noninvasive diagnosis of hepatic fibrosis in patients with chronic hepatitis C by splenic Doppler impedance index. Liu CH, et al. Clin Gastroenterol Hepatol. 2007 Oct;5(10):1199-1206.e1.
Deaths from chronic liver disease and viral hepatitis, Multnomah County, Oregon, 2000. Thomas AR, J Clin Gastroenterol. 2007 Oct;41(9):859-62.
C is the most common, chronic blood-borne